Evommune (NYSE:EVMN) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Evommune (NYSE:EVMN) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $35.00 target price on the stock.

Several other research firms also recently issued reports on EVMN. Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a report on Monday, December 1st. Zacks Research upgraded Evommune to a “hold” rating in a report on Tuesday, December 2nd. William Blair initiated coverage on shares of Evommune in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. Finally, Leerink Partners assumed coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “outperform” rating and a $42.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Evommune has an average rating of “Buy” and an average price target of $38.25.

Evommune Trading Up 4.6%

Shares of EVMN opened at $16.07 on Tuesday. Evommune has a 12 month low of $13.89 and a 12 month high of $24.03.

Evommune (NYSE:EVMN) last issued its quarterly earnings data on Thursday, December 11th. The company reported ($8.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.58) by ($1.49). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.